Official Title
Prognostic Significance of the TREM-1 Pathway Activation in COVID-19
Brief Summary

Severe Acute Respiratory Syndrome-Corona Virus-2 infection results in a mild infection in most of the patients. However, 15-20% require hospitalization, and among them, 15-20% will develop acute respiratory failure, leading to their admission in Intensive Care Unit. There are no accepted predictive criteria for aggravation. Severe forms of Coronavirus induced disease-19 (COVID-19) are the consequence of endotheliopathy, and hyperinflammatory and pro-coagulant state. The Triggering Receptor Expressed on Myeloid cells-1 (TREM-1) is an immunoreceptor that acts as an amplifier of the inflammatory response. TREM-1 is expressed on myeloid and endothelial cells. Its activation leads to endothelial activation and damage, hyperinflammatory, and pro-coagulant state. TREM-1 activation is associated with poor outcome during septic shock and myocardial infarction. We here aim at investigating the relationship between TREM-1 pathway activation and clinical degradation and outcome of COVID-19 hospitalized patients.

Completed
COVID19

Other: blood sampling

Blood will be collected every 3 days until Day 28, discharge, or death

Eligibility Criteria

Inclusion Criteria Consecutive COVID-19 hospitalized patients for less than 3 days

Exclusion Criteria:

No consent Pregnancy protected populations

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
France
Locations

CHRU Limoges
Limoges, France

Central hospital
Nancy, France

Central Hospital, Nancy, France
NCT Number
MeSH Terms
COVID-19